Analysts Set Pediatrix Medical Group, Inc. (NYSE:MD) Target Price at $17.08

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have received an average recommendation of “Hold” from the six analysts that are presently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $16.75.

Several equities research analysts have recently issued reports on the company. StockNews.com raised Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research report on Wednesday, January 22nd. UBS Group upped their price target on Pediatrix Medical Group from $16.50 to $18.50 and gave the stock a “neutral” rating in a report on Friday, February 21st. Macquarie began coverage on shares of Pediatrix Medical Group in a research note on Monday, December 16th. They issued an “outperform” rating and a $18.00 price objective on the stock. Finally, Truist Financial cut their target price on shares of Pediatrix Medical Group from $18.00 to $16.00 and set a “hold” rating for the company in a research note on Friday.

Institutional Trading of Pediatrix Medical Group

A number of large investors have recently bought and sold shares of MD. Vanguard Group Inc. raised its stake in shares of Pediatrix Medical Group by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 10,812,611 shares of the company’s stock valued at $141,861,000 after acquiring an additional 113,976 shares during the last quarter. State Street Corp raised its position in Pediatrix Medical Group by 1.4% in the 3rd quarter. State Street Corp now owns 3,540,791 shares of the company’s stock valued at $41,038,000 after purchasing an additional 50,597 shares during the last quarter. Pacer Advisors Inc. bought a new position in Pediatrix Medical Group in the 4th quarter valued at $35,492,000. Boston Partners boosted its stake in Pediatrix Medical Group by 25.2% in the fourth quarter. Boston Partners now owns 1,956,353 shares of the company’s stock worth $25,922,000 after purchasing an additional 393,600 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Pediatrix Medical Group by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 1,947,796 shares of the company’s stock worth $25,562,000 after purchasing an additional 11,045 shares during the last quarter. 97.71% of the stock is currently owned by institutional investors.

Pediatrix Medical Group Stock Up 0.6 %

Shares of Pediatrix Medical Group stock opened at $13.42 on Thursday. Pediatrix Medical Group has a 12-month low of $6.62 and a 12-month high of $17.67. The company has a quick ratio of 1.42, a current ratio of 1.60 and a debt-to-equity ratio of 0.81. The stock has a 50 day moving average price of $14.32 and a two-hundred day moving average price of $13.95. The stock has a market capitalization of $1.15 billion, a P/E ratio of -11.18, a PEG ratio of 1.74 and a beta of 1.32.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Thursday, February 20th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.12. The business had revenue of $502.36 million during the quarter, compared to the consensus estimate of $486.22 million. Pediatrix Medical Group had a negative net margin of 4.92% and a positive return on equity of 15.47%. Equities analysts expect that Pediatrix Medical Group will post 1.38 earnings per share for the current year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.